Prevalence of drug-drug interactions with pangenotypic direct-acting antivirals for hepatitis C and real-world care management in the United States: A retrospective observational study

Prevalence of drug-drug interactions with pangenotypic direct-acting antivirals for hepatitis C and real-world care management in the United States: A retrospective observational study

BACKGROUND: Direct-acting antiviral (DAA) regimens for hepatitis C virus (HCV) have varying potentials for drug-drug interactions (DDIs). OBJECTIVES: To (1) identify prevalence of potential DDI with glecaprevir-pibrentasvir (GLE-PIB) and sofosbuvir-velpatasvir (SOF-VEL) and (2) describe health care...

Full description

Bibliographic Details
Main Authors: Afdhal, N.H (Author), Curry, M.P (Author), Flamm, S.L (Author), Milligan, S. (Author), Tsai, N. (Author), Wick, N. (Author), Younossi, Z. (Author)
Format: Article
Language:English
Published: Academy of Managed Care Pharmacy (AMCP) 2021
Subjects:
adolescent
Adolescent
adult
Adult
aged
Aged
analgesic agent
anti human immunodeficiency virus agent
antiarrhythmic agent
anticoagulant agent
anticonvulsant therapy
anticonvulsive agent
antidiabetic agent
antihistaminic agent
antihypertensive agent
antihypertensive therapy
antiinfective agent
antilipemic agent
antineoplastic agent
Antiviral Agents
antivirus agent
anxiety
Article
atorvastatin
beta adrenergic receptor blocking agent
bronchodilating agent
buprenorphine
calcium channel blocking agent
cancer therapy
carbamazepine
Charlson Comorbidity Index
chi square test
contraceptive agent
data base
diabetes mellitus
drug classification
drug contraindication
drug effect
drug interaction
Drug Interactions
drug safety
dyslipidemia
electronic medical record
eltrombopag
esomeprazole
ethinylestradiol
etonogestrel
famotidine
female
Female
fentanyl
genotype
Genotype
glecaprevir plus pibrentasvir
health care organization
health care personnel
Hepacivirus
hepatitis C
Hepatitis C
Hepatitis C virus genotype 1
Hepatitis C virus genotype 2
Hepatitis C virus genotype 3
Hepatitis C virus genotype 4
Hepatitis C virus genotype 5
Hepatitis C virus genotype 6
histamine H2 receptor antagonist
human
Human immunodeficiency virus infection
Human immunodeficiency virus proteinase inhibitor
Humans
hydrocodone
hypertension
immunosuppressive agent
levonorgestrel
major clinical study
male
Male
middle aged
Middle Aged
neuroleptic agent
nonnucleoside reverse transcriptase inhibitor
observational study
omeprazole
oxcarbazepine
oxycodone
pantoprazole
pharmacist
phenobarbital
phenytoin
prevalence
Prevalence
proton pump inhibitor
ranitidine
Retrospective Studies
retrospective study
rifampicin
RNA directed DNA polymerase inhibitor
simvastatin
sofosbuvir plus velpatasvir
specialty pharmacy
steroid
United States
urinary tract agent
young adult
Young Adult
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items